PDCD1 and melanoma: A significant study involving large cohorts of stage III or IV melanoma patients found that pairing anti-LAG3 antibodies with anti-PD-1 antibodies considerably enhanced progression-free survival compared to using anti-PD-1 antibodies alone [53].